Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
about
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesClinical trial data in support of changing guidelines in osteoarthritis treatment.Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.Effects of parecoxib on analgesia benefit and blood loss following open prostatectomy: a multicentre randomized trial.Topical nonsteroidal anti-inflammatory drugs for management of osteoarthritis in long-term care patients.Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel's View on Preventable Harm Associated with NSAID Therapy.Duloxetine in the management of chronic musculoskeletal painAnalysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more.Opioid therapy for osteoarthritis and chronic low back pain.Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.Topical therapies for osteoarthritis.The NSAID dilemma: managing osteoarthritis in high-risk patients.A review of opioids for in-hospital pain management.A review of pharmacotherapy for chronic low back pain with considerations for sports medicine.Chronic low back pain: pharmacological, interventional and surgical strategies.Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy - A Population-Based Register Study.Prevention and Treatment of NSAID Gastropathy.Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database.
P2860
Q24632951-79E42785-A6C8-4657-AAAD-EE6F78A4DDA3Q30804806-E90F7AAD-0F41-4ECC-89DF-C2BFF57286EAQ34474985-45F5D64D-45C3-4666-B352-2BFDE2838C19Q35170196-0A550497-965A-49FF-AF04-D5B8DDE8EB7DQ35526741-E80A147C-0BC9-4351-AC46-84001127DE09Q35779455-33BE9619-7C11-405F-8AC2-3AFC19BE84AFQ36071024-F5B91A47-C449-4C60-9614-4CDA589BDEF6Q37233377-DD2C4A05-95C6-488B-A3AB-A373DFAA03A1Q37810414-F9340FDA-0761-4EE8-A4DA-B82458B676C9Q37832976-25BC9D50-BAB2-4BA9-BF08-5CD0CBD3E6E2Q37902642-6AB71BE6-61B8-4791-A2A1-32C59838E78EQ37949849-46F53CC0-C3C3-42CF-9E17-A7290393BB24Q37992490-4B61FC6C-64F9-454B-BA82-B43024AE977AQ38073084-CAD9FF62-C86F-4E96-A314-5F53323B9D93Q38118585-4990EEDC-6808-4014-A19A-3275EDC6F702Q38417110-727020F5-5654-4F8B-92E8-2BF8EE915A8EQ41744470-7B37FD1A-90E0-4356-91BF-1A452B89FF09Q44848854-2F47AFC8-DA0A-4E52-A65B-3C3640ED98C8
P2860
Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Gastrointestinal safety of non ...... itors in patients on warfarin.
@en
Gastrointestinal safety of non ...... itors in patients on warfarin.
@nl
type
label
Gastrointestinal safety of non ...... itors in patients on warfarin.
@en
Gastrointestinal safety of non ...... itors in patients on warfarin.
@nl
prefLabel
Gastrointestinal safety of non ...... itors in patients on warfarin.
@en
Gastrointestinal safety of non ...... itors in patients on warfarin.
@nl
P2093
P2860
P356
P1476
Gastrointestinal safety of non ...... itors in patients on warfarin.
@en
P2093
Felicia Bixler
Gerald Levy
T Craig Cheetham
P2860
P304
P356
10.1345/APH.1M284
P407
P577
2009-10-06T00:00:00Z